Current drug delivery · 2017
Gold Nanoparticles Conjugated Levofloxacin: For Improved Antibacterial Activity Over Levofloxacin Alone.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bagga Paramdeep, Siddiqui Hifazat Hussain, Akhtar Juber, Mahmood Tariq, Zahera Manaal, Khan Mohd Sajid
Аннотация
BACKGROUND: Levofloxacin is a potent antibiotic with severe side effects due to its high doses. Bacterial resistance may be due to frequent use of antibiotics. Biogenic gold nanoparticles conjugated levofloxacin (Au-HSA-LvN-NPs) were developed by Human Serum Albumin (HSA) and nitrate reductasemediated pathways.
METHODS: Au-HSA-LvN-NPs (size = 27.2 ± 1 nm) were readily generated with high emulsion stability zeta potential (-13.3 mV). The developed nanoparticles were also characterized by UVvisible spectroscopy, Transmission Electron Microscopy and Dynamic Light Scattering techniques.
RESULTS: The optimized nanoparticles were found efficient against both Gram-positive bacteria and Gramnegative bacteria specifically S. aureus (MIC-0.373 µg/ml), E. coli (MIC-0.149 µg/ml) and P. aeruginosa (MIC-0.346 µg/ml) respectively.
CONCLUSION: The efficiency of bioconjugated levofloxacin got improved by 1.94 times, 2.89 times and 1.46 times against S. aureus, E. coli and P. aeruginosa respectively, in comparison to pure levofloxacin.
METHODS: Au-HSA-LvN-NPs (size = 27.2 ± 1 nm) were readily generated with high emulsion stability zeta potential (-13.3 mV). The developed nanoparticles were also characterized by UVvisible spectroscopy, Transmission Electron Microscopy and Dynamic Light Scattering techniques.
RESULTS: The optimized nanoparticles were found efficient against both Gram-positive bacteria and Gramnegative bacteria specifically S. aureus (MIC-0.373 µg/ml), E. coli (MIC-0.149 µg/ml) and P. aeruginosa (MIC-0.346 µg/ml) respectively.
CONCLUSION: The efficiency of bioconjugated levofloxacin got improved by 1.94 times, 2.89 times and 1.46 times against S. aureus, E. coli and P. aeruginosa respectively, in comparison to pure levofloxacin.